Direct-to-Consumer Surgery: Non-invasive liposuction for the masses

Not so very long ago, reimbursement was king in the world of medical devices. But the overnight success of injectible anti-wrinkle drug Botox signalled a change in the market. Now device companies developing liposuction alternatives hope to repeat that success, perhaps most importantly, in building their businesses outside of traditional reimbursement circles with a largely consumer-driven or self-pay market with new devices for cosmetic surgery applications.

Not so very long ago, reimbursement was king in the world of medical devices. Without reimbursement, there was no market, particularly for devices that had any degree of invasiveness to them. For that reason, if companies with surgical or even minimally invasive devices dreamed of one day selling to the virtually unlimited consumer market, they took the high road to the marketplace, by targeting a dire, and reimbursable, medical need first. Thus, Allergan Inc. , which had a multi-focal lens that could help the middle aged see both near and far without reading glasses, positioned its implantable device for the cataract market. Medtronic Inc. , looking into the market for obesity devices, got its electrical stimulation device approved for gastroparesis, an uncommon but horrendous disorder that causes frequent vomiting. (See "Obesity: Supersized Medical Device Market Also see "Obesity: Super-Sized Medical Device Market " - Medtech Insight, 1 March, 2003.) And injectable anti-wrinkle drug Botox (botulinum toxin) first entered the market as a therapy for a rare facial twitching disorder. But things are changing, and it was perhaps the overnight success of Botox that first signaled this shift.

Botox has boomed since its introduction in 2000; there were 1.6 million Botox injections in 2002, up 4% over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

FDA Outlines Responsibilities For Owners Of Transferred 510(k)s

 
• By 

The US FDA's new draft guidance details the responsibilities of new owners of 510(k) clearances, including making timely updates device listings in FURLS and GUDID to maintain accurate information for safety alerts and recalls. Comments on the draft are accepted until 4 August.

US House Budget Sets FDA FY26 Funding At $3.2B

 

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

 
• By 

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

More from Medtech Insight

Execs On The Move: 26-30 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

 
• By 

While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.